Vorolanib
Showing 1 - 11 of 11
Thymic Carcinoma, NSCLC, Refractory Thoracic Tumors Trial in United States (VEGFR/PDGFR Dual Kinase Inhibitor X-82, Nivolumab)
Active, not recruiting
- Thymic Carcinoma
- +3 more
- VEGFR/PDGFR Dual Kinase Inhibitor X-82
- Nivolumab
-
Palo Alto, California
- +6 more
Sep 21, 2022
Solid Tumor, Hepatocellular Carcinoma, Gastric Cancer Trial in Saint Louis (Vorolanib, Nivolumab, Pembrolizumab)
Terminated
- Solid Tumor
- +3 more
- Vorolanib
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Jul 27, 2020
Advanced Malignant Solid Tumors Trial in Shanghai (CM082)
Active, not recruiting
- Advanced Malignant Solid Tumors
-
Shanghai, Shanghai, ChinaShanghai East Hospital
Nov 10, 2022
Advanced Solid Tumor Trial in Nanjing ([14]CM082 suspension)
Active, not recruiting
- Advanced Solid Tumor
- [14]CM082 suspension
-
Nanjing, Jiangsu, ChinaJiangsu Province Hospital Affiliated to Nanjing Madical Universi
Nov 24, 2021
Advanced Malignant Solid Tumors Trial in Hangzhou (CM082 tablet (test product), CM082 tablet (reference product))
Completed
- Advanced Malignant Solid Tumors
- CM082 tablet (test product)
- CM082 tablet (reference product)
-
Hangzhou, Zhejiang, ChinaThe 1st Phase Clinical Research Center of the Second Affiliated
Nov 24, 2021
Renal Cell Cancer Metastatic Trial in Beijing (CM082 combined with everolimus, CM082, Everolimus)
Unknown status
- Renal Cell Cancer Metastatic
- CM082 combined with everolimus
- +2 more
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Feb 4, 2021
Myopic Choroidal Neovascularisation Trial in Beijing (CM082)
Suspended
- Myopic Choroidal Neovascularisation
-
Beijing, ChinaPeking Union Medical College Hospital
Mar 7, 2021
Advanced Malignant Solid Tumors Trial in Hangzhou (CM082 with fed or fasting)
Completed
- Advanced Malignant Solid Tumors
- CM082 with fed or fasting
-
Hangzhou, Zhejiang, ChinaThe 1st Phase Clinical Research Center of the Second Affiliated
May 20, 2020
Age-Related Macular Degeneration Trial in China (CM082 tablet)
Suspended
- Age-Related Macular Degeneration
- CM082 tablet
-
Beijing, Beijing, China
- +5 more
Jan 8, 2020
Age-Related Macular Degeneration Trial in Wuhan (CM082)
Unknown status
- Age-Related Macular Degeneration
-
Wuhan, Hubei, ChinaRenmin Hospital of Wuhan University, Hubei General Hospital
Jan 8, 2020
Advanced Cancer Trial in Beijing, Tianjin (CM082 Tablet)
Completed
- Advanced Cancer
- CM082 Tablet
-
Beijing, Beijing, China
- +2 more
Jul 2, 2019